{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:19Z","timestamp":1780124479558,"version":"3.54.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03565-9","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:04:48Z","timestamp":1774944288000},"page":"2371-2386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Isabelle","family":"Whittle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brown Hajdukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Perrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyran","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"2","key":"3565_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"SS Seyedian","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113\u201322.","journal-title":"J Med Life"},{"issue":"3","key":"3565_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13(3):e065186.","journal-title":"BMJ Open"},{"issue":"5","key":"3565_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","volume":"6","author":"B Brigida","year":"2021","unstructured":"Brigida B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3565_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014part I. Inflamm Bowel Dis. 2018;24(4):742\u201351.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3565_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-0115-2","volume":"4","author":"DP Hudesman","year":"2020","unstructured":"Hudesman DP, Chakravarty SD, Emond B, et al. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol. 2020;4(1):16.","journal-title":"BMC Rheumatol"},{"issue":"3","key":"3565_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","volume":"17","author":"E Schoefs","year":"2023","unstructured":"Schoefs E, Vermeire S, Ferrante M, et al. What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study. J Crohns Colitis. 2023;17(3):379\u201388.","journal-title":"J Crohns Colitis"},{"key":"3565_CR7","unstructured":"National Institute for Health and Care Excellence. Ulcerative colitis: management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng130. Accessed 22 Oct 2024."},{"key":"3565_CR8","unstructured":"National Institute for Health and Care Excellence. Crohn\u2019s disease: management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng129. Accessed 22 Oct 2024."},{"issue":"6","key":"3565_CR9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","volume":"140","author":"D Burger","year":"2011","unstructured":"Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(6):1827-37.e2.","journal-title":"Gastroenterology"},{"issue":"4","key":"3565_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000535647","volume":"42","author":"A Sokic-Milutinovic","year":"2024","unstructured":"Sokic-Milutinovic A, Milosavljevic T. Inflammatory bowel disease: from conventional immunosuppression to biologic therapy. Dig Dis. 2024;42(4):325\u201335.","journal-title":"Dig Dis"},{"issue":"675","key":"3565_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3399\/bjgp18X699341","volume":"68","author":"K Barrett","year":"2018","unstructured":"Barrett K, Saxena S, Pollok R. Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care. Br J Gen Pract. 2018;68(675):497\u20138.","journal-title":"Br J Gen Pract"},{"key":"3565_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109545","volume":"114","author":"C Dai","year":"2023","unstructured":"Dai C, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: current evidence and perspectives. Int Immunopharmacol. 2023;114:109545.","journal-title":"Int Immunopharmacol"},{"issue":"29","key":"3565_CR13","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","volume":"29","author":"LF Wang","year":"2023","unstructured":"Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: a literature review. World J Gastroenterol. 2023;29(29):4481\u201398.","journal-title":"World J Gastroenterol"},{"key":"3565_CR14","unstructured":"IBD Relief. Colectomy surgery for inflammatory bowel disease (IBD). https:\/\/www.ibdrelief.com\/learn\/treatment\/surgery\/colectomy-surgery-for-ibd. Accessed 24 Mar 2025."},{"key":"3565_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.01.013","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Van Assche G, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016. https:\/\/doi.org\/10.1016\/j.dld.2016.01.013.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3565_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","volume":"28","author":"VM Montori","year":"2023","unstructured":"Montori VM, Ruissen MM, Hargraves IG, Brito JP, Kunneman M. Shared decision-making as a method of care. BMJ Evid Based Med. 2023;28(4):213\u20137.","journal-title":"BMJ Evid Based Med"},{"issue":"11","key":"3565_CR17","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jval.2019.04.1930","volume":"22","author":"SPI Huls","year":"2019","unstructured":"Huls SPI, Whichello CL, van Exel J, de Uyl- Groot CA, de Bekker-Grob EW. What is next for patient preferences in health technology assessment? A systematic review of the challenges. Value Health. 2019;22(11):1318\u201328.","journal-title":"Value Health"},{"key":"3565_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.470","author":"CV Almario","year":"2018","unstructured":"Almario CV, Keller MS, Chen M, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018. https:\/\/doi.org\/10.1038\/ajg.2017.470.","journal-title":"Am J Gastroenterol"},{"key":"3565_CR19","doi-asserted-by":"crossref","unstructured":"Atreya R, Redondo I, Streit P, et al. Treatment satisfaction among ulcerative colitis patients with and without bowel urgency\u2014a global real-world analysis. American Gastroenterological Association abstracts. 2023. p. 164.","DOI":"10.1016\/S0016-5085(23)02599-4"},{"key":"3565_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000203638","volume":"79","author":"JE Baars","year":"2009","unstructured":"Baars JE, Siegel CA, Kuipers EJ, Van Der Woude CJ. Patient\u2019s perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion. 2009;79:30\u20135.","journal-title":"Digestion"},{"key":"3565_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/CEG.S206970","volume":"12","author":"M Boeri","year":"2019","unstructured":"Boeri M, Myers K, Ervin C, et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019;12:263\u201378.","journal-title":"Clin Exp Gastroenterol"},{"key":"3565_CR22","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.3390\/jcm11195669","volume":"11","author":"G Burdge","year":"2022","unstructured":"Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger CP. Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations. J Clin Med. 2022;11:5669.","journal-title":"J Clin Med"},{"key":"3565_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/MEG.0000000000000658","volume":"28","author":"D Carpio","year":"2016","unstructured":"Carpio D, Lopez-Sanroman A, Calvet X, et al. Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey. Eur J Gastroenterol Hepatol. 2016;28:1056\u201364.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"3565_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.dld.2016.06.036","volume":"48","author":"F Casellas","year":"2016","unstructured":"Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: results of a Delphi study among patients and physicians. Dig Liver Dis. 2016;48(10):1172\u20139.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"3565_CR25","doi-asserted-by":"publisher","first-page":"otac035","DOI":"10.1093\/crocol\/otac035","volume":"4","author":"A Charabaty","year":"2022","unstructured":"Charabaty A, Schneider B, Zambrano JA, Keefer L. living with inflammatory bowel disease: online surveys evaluating patient perspectives on treatment satisfaction and health-related quality of life. Crohns Colitis 360. 2022;4(3):otac035.","journal-title":"Crohns Colitis 360"},{"issue":"9","key":"3565_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093094","volume":"12","author":"F D\u2019Amico","year":"2023","unstructured":"D\u2019Amico F, Vieujean S, Caron B, Peyrin-Biroulet L, Danese S. Risk-benefit of IBD drugs: a physicians and patients survey. J Clin Med. 2023;12(9):3094.","journal-title":"J Clin Med"},{"issue":"12","key":"3565_CR27","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/ibd\/izae015","volume":"30","author":"G Fiorino","year":"2024","unstructured":"Fiorino G, Bent-Ennakhil N, Varriale P, Braegger F, Hoefkens E. Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven European countries using a discrete choice experiment. Inflamm Bowel Dis. 2024;30(12):2380\u201394.","journal-title":"Inflamm Bowel Dis"},{"key":"3565_CR28","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Schreiber S, Siegel CA, et al. Benefit-risk trade-offs and patient preferences for therapy selection in ulcerative colitis: a multi-country preference study. J Crohns Colitis. 2024;18(Supplement_1):i1077-i9.","DOI":"10.1093\/ecco-jcc\/jjad212.0681"},{"issue":"10","key":"3565_CR29","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1365-2036.2009.03972.x","volume":"29","author":"JR Gray","year":"2009","unstructured":"Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient\u2019s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther. 2009;29(10):1114\u201320.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3565_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/03007995.2020.1716704","volume":"36","author":"LM Hagelund","year":"2020","unstructured":"Hagelund LM, Elkjaer Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis-results from a survey study. Curr Med Res Opin. 2020;36(5):771\u20139.","journal-title":"Curr Med Res Opin"},{"key":"3565_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-230X-7-20","volume":"7","author":"NJ Hall","year":"2007","unstructured":"Hall NJ, Rubin GP, Hungin APS, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol. 2007;7:20.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3565_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227635","volume":"15","author":"GS Hazlewood","year":"2020","unstructured":"Hazlewood GS, Pokharel G, Deardon R, et al. Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment. PLoS ONE. 2020;15(1):e0227635.","journal-title":"PLoS ONE"},{"issue":"4","key":"3565_CR33","doi-asserted-by":"publisher","first-page":"otaf073","DOI":"10.1093\/crocol\/otad073","volume":"5","author":"C Khalil","year":"2023","unstructured":"Khalil C, van Deen WK, Dupuy T, et al. Patients\u2019 perspectives, experiences, and concerns with perianal fistulae: insights from online targeted-disease forums. Crohns Colitis 360. 2023;5(4):otaf073.","journal-title":"Crohns Colitis 360"},{"issue":"2","key":"3565_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11314880-000000000-00000","volume":"3","author":"GR Lichtenstein","year":"2010","unstructured":"Lichtenstein GR, Waters HC, Kelly J, et al. Assessing drug treatment preferences of patients with Crohn\u2019s disease: a conjoint analysis. Patient Auckl. 2010;3(2):113\u201323.","journal-title":"Patient Auckl"},{"issue":"12","key":"3565_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/01.mib.0000235831.01682.8d","volume":"12","author":"EV Loftus Jr","year":"2006","unstructured":"Loftus EV Jr. A practical perspective on ulcerative colitis: patients\u2019 needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12):1107\u201313.","journal-title":"Inflamm Bowel Dis"},{"issue":"32","key":"3565_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007800","volume":"96","author":"T Mizoshita","year":"2017","unstructured":"Mizoshita T, Katano T, Tanida S, et al. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017;96(32):e7800.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"3565_CR37","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ibd\/izaa311","volume":"27","author":"DB Patel","year":"2021","unstructured":"Patel DB, Van Deen WK, Almario CV, et al. Assessing patient decision-making on biologic and small-molecule therapies in inflammatory bowel diseases: insights from a conjoint analysis in the United States, Canada, and the United Kingdom. Inflamm Bowel Dis. 2021;27(10):1593\u2013601.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"3565_CR38","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/ibd\/izab006","volume":"27","author":"DT Rubin","year":"2021","unstructured":"Rubin DT, Sninsky C, Siegmund B, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflamm Bowel Dis. 2021;27(12):1942\u201353.","journal-title":"Inflamm Bowel Dis"},{"issue":"12S","key":"3565_CR39","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.14309\/01.ajg.0000995948.67877.b3","volume":"118","author":"B Schneider","year":"2023","unstructured":"Schneider B. Patient-reported impact of irritable bowel disease and desired treatment outcomes desired treatment outcomes. Am J Gastroenterol. 2023;118(12S):S14.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"3565_CR40","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","volume":"39","author":"S Schubert","year":"2022","unstructured":"Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory bowel disease patients\u2019 treatment preferences using a discrete choice experiment technique: the InPuT study. Adv Ther. 2022;39(6):2889\u2013905.","journal-title":"Adv Ther"},{"issue":"3","key":"3565_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/00365521.2023.2286191","volume":"59","author":"T Straatmijer","year":"2024","unstructured":"Straatmijer T, van den Akker-van Marle ME, Ponsioen CY, et al. Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment. Scand J Gastroenterol. 2024;59(3):288\u201395.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"3565_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175826","volume":"12","author":"E Sullivan","year":"2017","unstructured":"Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn\u2019s disease across Germany. PLoS ONE. 2017;12(4):e0175826.","journal-title":"PLoS ONE"},{"issue":"3","key":"3565_CR43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000528586","volume":"41","author":"WK Van Deen","year":"2023","unstructured":"Van Deen WK, Khalil C, Bonthala NN, et al. Inflammatory bowel disease patients\u2019 preferences for subcutaneous versus intravenous therapies: a mixed-methods study. Dig Dis. 2023;41(3):412\u201321.","journal-title":"Dig Dis"},{"issue":"8","key":"3565_CR44","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/ibd.21888","volume":"18","author":"SR Vavricka","year":"2012","unstructured":"Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18(8):1523\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"3565_CR45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00365521.2022.2036808","volume":"57","author":"N Wickramasekera","year":"2022","unstructured":"Wickramasekera N, Coates E, Barr A, et al. Patient preferences for treatment in steroid resistant ulcerative colitis-a discrete-choice experiment. Scand J Gastroenterol. 2022;57(7):797\u2013806.","journal-title":"Scand J Gastroenterol"},{"key":"3565_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.736149","volume":"12","author":"L Yao","year":"2021","unstructured":"Yao L, Zhu X, Shao B, et al. Reasons and factors contributing to Chinese patients\u2019 preference for ustekinumab in Crohn\u2019s disease: a multicenter cross-sectional study. Front Pharmacol. 2021;12:736149.","journal-title":"Front Pharmacol"},{"issue":"9","key":"3565_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jgh3.12627","volume":"5","author":"SJ Connor","year":"2021","unstructured":"Connor SJ, Sechi A, Andrade M, Deuring JJ, Witcombe D. Ulcerative colitis narrative findings: Australian survey data comparing patient and physician disease management views. JGH Open. 2021;5(9):1033\u201340.","journal-title":"JGH Open"},{"issue":"2","key":"3565_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","volume":"17","author":"E Louis","year":"2023","unstructured":"Louis E, Siegel CA, James B, Heidenreich S, Krucien N, Ghosh S. Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]. J Crohns Colitis. 2023;17(2):231\u20139.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3565_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02640-7","volume":"23","author":"A Armuzzi","year":"2023","unstructured":"Armuzzi A, Hart A, Cappelleri JC, et al. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC Gastroenterol. 2023;23(1):17.","journal-title":"BMC Gastroenterol"},{"key":"3565_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae119","author":"J Burisch","year":"2024","unstructured":"Burisch J, Hart A, Sturm A, et al. Residual disease burden among European patients with inflammatory bowel disease: a real-world survey. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae119.","journal-title":"Inflamm Bowel Dis"},{"key":"3565_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/00365520801912011","volume":"43","author":"J Haapamaki","year":"2008","unstructured":"Haapamaki J, Turunen U, Roine RP, Faarkkilaa MA, Arkkila PET. Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. Scand J Gastroenterol. 2008;43:821\u201330.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"3565_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12325-023-02712-w","volume":"41","author":"R Jin","year":"2024","unstructured":"Jin R, Nduka C, Courmier D, et al. Real-world experience of adalimumab biosimilar (ABP 501) use in patients with inflammatory bowel disease in Europe. Adv Ther. 2024;41(1):331\u201348.","journal-title":"Adv Ther"},{"key":"3565_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-9-17","volume":"9","author":"C Pieper","year":"2009","unstructured":"Pieper C, Haag S, Gesenhues S, Holtmann G, Gerken G, Jockel KH. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders - an evaluation study. BMC Health Serv Res. 2009;9:17.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"3565_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.15403\/jgld.2014.1121.274.tor","volume":"27","author":"M Simsek","year":"2018","unstructured":"Simsek M, Markus-De Kwaadsteniet TML, van der Horst D, Mulder CJJ, de Boer NKH. Patient-reported experiences with a relicensed generic: thioguanine for the treatment of inflammatory bowel diseases. J Gastrointest Liver Dis. 2018;27(4):385\u20139.","journal-title":"J Gastrointest Liver Dis"},{"issue":"3","key":"3565_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.crohns.2009.12.012","volume":"4","author":"G Van Assche","year":"2010","unstructured":"Van Assche G, Vermeire S, Noman M, et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis. 2010;4(3):329\u201333.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"3565_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaa030","volume":"2","author":"S Yanai","year":"2020","unstructured":"Yanai S, Toya Y, Nakamura S, Matsumoto T. Patients\u2019 preference of topical therapy for ulcerative colitis in Japan: a web-based 3T survey. Crohns Colitis 360. 2020;2(2):otaa030.","journal-title":"Crohns Colitis 360"},{"key":"3565_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-1","author":"PB Allen","year":"2010","unstructured":"Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010. https:\/\/doi.org\/10.1186\/1471-230X-10-1.","journal-title":"BMC Gastroenterol"},{"issue":"Supplement_1","key":"3565_CR58","doi-asserted-by":"publisher","first-page":"i1019","DOI":"10.1093\/ecco-jcc\/jjad212.0650","volume":"18","author":"M Argollo","year":"2024","unstructured":"Argollo M, An YK, Balderramo D, et al. Preferences towards treatment attributes among patients with Crohn\u2019s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment. J Crohns Colitis. 2024;18(Supplement_1):i1019\u201320.","journal-title":"J Crohns Colitis"},{"issue":"10S","key":"3565_CR59","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.14309\/01.ajg.0000860728.41531.11","volume":"117","author":"A Athavale","year":"2022","unstructured":"Athavale A, Edelblut J, Chen M, et al. Treatment preferences in Crohn\u2019s disease perianal fistula: patient perspectives. Am J Gastroenterol. 2022;117(10S):e740\u20131.","journal-title":"Am J Gastroenterol"},{"issue":"Supplement_1","key":"3565_CR60","doi-asserted-by":"publisher","first-page":"i618","DOI":"10.1093\/ecco-jcc\/jjac190.0618","volume":"17","author":"B Caballol Oliva","year":"2023","unstructured":"Caballol Oliva B, Fernandez-Clotet A, Panes J, et al. Switch from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: efficacy, safety and patients\u2019 acceptance. J Crohns Colitis. 2023;17(Supplement_1):i618-i.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 8","key":"3565_CR61","first-page":"983","volume":"11","author":"JR Campion","year":"2023","unstructured":"Campion JR, Finn K, Keogh A, et al. Cost and convenience: major drivers of patient preference on route of biologic administration. United European Gastroenterol J. 2023;11(Suppl 8):983","journal-title":"United European Gastroenterol J"},{"key":"3565_CR62","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241265776","author":"B Caron","year":"2024","unstructured":"Caron B, Seksik P, Buisson A, et al. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Ther Adv Gastroenterol. 2024. https:\/\/doi.org\/10.1177\/17562848241265776.","journal-title":"Ther Adv Gastroenterol"},{"issue":"9","key":"3565_CR63","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","volume":"15","author":"D Denesh","year":"2021","unstructured":"Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol. 2021;15(9):1091\u20136.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"3565_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1398","volume":"18","author":"G Dewitte","year":"2024","unstructured":"Dewitte G, Akhayad S, Truyens M, Geldof J, Lobaton T. Disease outcomes and patient\u2019s perspectives after switching biologics from intravenous to subcutaneous administration. A real-world experience in a tertiary IBD-unit. J Crohns Colitis. 2024;18(Supplement_1):i2232.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"3565_CR65","first-page":"752","volume":"164","author":"B Goodwin","year":"2023","unstructured":"Goodwin B, Cazzetta S, Chen ML, et al. Patient and physician perspectives on the impact of Crohn\u2019s perianal fistulas on patient life, unmet needs with current treatment options and willingness to use emerging methods. Gastroenterology. 2023;164(6):752.","journal-title":"Gastroenterology"},{"issue":"1","key":"3565_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000530139","volume":"8","author":"X Hebuterne","year":"2023","unstructured":"Hebuterne X, Vavricka SR, Thorne HC, MacKenzie-Smith L, Laoun R, Burisch J. Medication formulation preference of mild and moderate ulcerative colitis patients: a European survey. Inflamm Intest Dis. 2023;8(1):41\u20139.","journal-title":"Inflamm Intest Dis"},{"issue":"3","key":"3565_CR67","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5009\/gnl15126","volume":"10","author":"ES Kim","year":"2016","unstructured":"Kim ES, Kim KO, Jang BI, et al. Factors contributing to the preference of Korean patients with Crohn\u2019s disease when selecting an anti-tumor necrosis factor agent (choice study). Gut Liver. 2016;10(3):391\u20138.","journal-title":"Gut Liver"},{"issue":"1","key":"3565_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000493346","volume":"3","author":"L MacKenzie-Smith","year":"2018","unstructured":"MacKenzie-Smith L, Marchi P, Thorne H, Timeus S, Young R, Le Calve P. Patient preference and physician perceptions of patient preference for oral pharmaceutical formulations: results from a real-life survey. Inflamm Intest Dis. 2018;3(1):43\u201351.","journal-title":"Inflamm Intest Dis"},{"issue":"4","key":"3565_CR69","doi-asserted-by":"publisher","first-page":"otad069","DOI":"10.1093\/crocol\/otad069","volume":"5","author":"T Matsumoto","year":"2023","unstructured":"Matsumoto T, Imai K, Goda Y, et al. Questionnaire survey for inflammatory bowel disease patients in Japan; a web-based Japan, Crohn\u2019s disease, ulcerative colitis, patients survey. Crohns Colitis 360. 2023;5(4):otad069.","journal-title":"Crohns Colitis 360"},{"key":"3565_CR70","doi-asserted-by":"crossref","unstructured":"Moon W, Park SJ, Kim JH. The preference for controlled-release mesalazine formulation of 2 g-granule sachet in patients already experienced 1 g-tablet. J Crohns Colitis. 2024;18(Supplement_1):i1042-i4.","DOI":"10.1093\/ecco-jcc\/jjad212.0664"},{"issue":"1","key":"3565_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12664-023-01500-2","volume":"43","author":"D Napolitano","year":"2024","unstructured":"Napolitano D, Settanni CR, Parisio L, et al. Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: an online survey of patients. Indian J Gastroenterol. 2024;43(1):215\u201325.","journal-title":"Indian J Gastroenterol"},{"key":"3565_CR72","doi-asserted-by":"crossref","unstructured":"Pittet V, Rogler G, Seibold F. Reasons for low use of topical 5-ASA formulations in patients treated for ulcerative colitis: comparison of doctors and patients perspectives. J Crohns Colitis. 2024;18(Supplement_1):i1091-i.","DOI":"10.1093\/ecco-jcc\/jjad212.0691"},{"issue":"9","key":"3565_CR73","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","volume":"16","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study. J Crohns Colitis. 2022;16(9):1436\u201346.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3565_CR74","first-page":"22","volume":"4","author":"K Szanto","year":"2018","unstructured":"Szanto K, Rutka M, Milassin A, et al. How do you like the pen? Patients\u2019 opinion about switching adalimumab from prefilled syringe to pen in inflammatory bowel disease. Cent Eur J Gastroenterol Hepatol. 2018;4(1):22\u20136.","journal-title":"Cent Eur J Gastroenterol Hepatol"},{"key":"3565_CR75","doi-asserted-by":"publisher","unstructured":"Taxonera C, Martinez-Montiel MP, Barreiro-de-Acosta M, et al. Preferences and satisfaction of IBD patients after switching from adalimumab 40\u00a0mg weekly to 80\u00a0mg every other week given as a single injection: the ADASCAL study. Therap Adv Gastroenterol. 2021;14. https:\/\/doi.org\/10.1177\/17562848211056157.","DOI":"10.1177\/17562848211056157"},{"key":"3565_CR76","doi-asserted-by":"crossref","unstructured":"Todeschini A, Geccherle A, Signoretto P, Fasoli E, Variola A. Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with inflammatory bowel disease. J Crohns Colitis. 2023;17(Supplement_1):i551-i2.","DOI":"10.1093\/ecco-jcc\/jjac190.0552"},{"issue":"8","key":"3565_CR77","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/00365521.2023.2176252","volume":"58","author":"TH Wiken","year":"2023","unstructured":"Wiken TH, Hoivik ML, Buer L, et al. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol. 2023;58(8):863\u201373.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"3565_CR78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1590\/s0004-2803.202000000-86","volume":"57","author":"AA Wu","year":"2020","unstructured":"Wu AA, de Barros JR, Ramdeen M, Baima JP, Saad-Hossne R, Sassaki LY. Factors associated with patient\u2019s preference in choosing their therapy for inflammatory bowel disease in Brazil. Arq Gastroenterol. 2020;57(4):491\u20137.","journal-title":"Arq Gastroenterol"},{"issue":"5","key":"3565_CR79","first-page":"308","volume":"12","author":"MJ Kingsley","year":"2016","unstructured":"Kingsley MJ, Abreu MT. A personalized approach to managing inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(5):308\u201315.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03565-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03565-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03565-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:02Z","timestamp":1780120982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03565-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3565"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03565-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Isabelle Whittle, Richard Perry, Lisa Perrett, Natasha Perry and Hannah Coles are employees of Adelphi Values PROVE, which received funding from Sanofi to conduct this research. Kyran Jones was an employee of Sanofi at the time of writing and preparation of the manuscript, and Eva Brown Hajdukova works as a consultant for Sanofi and may hold stock options in the company. Kyron Jones is currently at Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human or animal participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}